周二，摩根士丹利重申了对Sarepta Therapeutics的积极立场，维持其增持评级和200.00美元的目标价。这家金融公司的分析是在Sarepta宣布一项重大合作协议后进行的，预计该协议将增强其研发能力。

周二，美银美林维持对Sarepta Therapeutics (NASDAQ:SRPT)的积极立场，重申"优于大市"评级，目标价为$200.00。该公司的乐观情绪源于Sarepta最近与Arrowhead达成的全球许可和合作协议，预计这将显著增强Sarepta的产品管线。

Arrowhead Pharmaceuticals (ARWR) has secured a new partnership with Sarepta Therapeutics (SRPT). Under the terms of the deal, ...

Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for ...

Shares of Arrowhead Pharmaceuticals catapulted Tuesday after the company inked a broad licensing deal with Sarepta ...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) added ~21% in the premarket on Tuesday after the company announced a global licensing ...

Sarepta Therapeutics said Tuesday that it will pay Arrowhead Pharmaceuticals $500 million in cash for a series of ...

Don't Miss our Black Friday Offers: An announcement from Sarepta Therapeutics ( (SRPT)) is now available. Sarepta Therapeutics is undergoing a leadership change as Ryan Brown steps down, with Cristin ...

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) shares are trading higher Tuesday after the company announced a global ...

Oppenheimer analyst Andreas Argyrides maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of ...

Sarepta Therapeutics and Arrowhead Pharmaceuticals said they have entered a licensing and collaboration agreement worth more than $1 billion.

Analysts have set 12-month price targets for Sarepta Therapeutics, revealing an average target of $168.79, a high estimate of ...